

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6044017

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
QUANTICEL PHARMACEUTICALS, INC.	04/08/2016
RECEIVING PARTY DATA	
Name:	CELGENE QUANTICEL RESEARCH, INC.
Street Address:	9393 TOWNE CENTRE DRIVE
City:	SAN DIEGO
State/Country:	CALIFORNIA
Postal Code:	92121
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	16007937
Application Number:	15687251
Application Number:	15401894
Application Number:	14988022
CORRESPONDENCE DATA	
Fax Number:	(202)672-5399
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	202-672-5300
Email:	swalker@foley.com, ipdocketing@foley.com
Correspondent Name:	MICHELE M. SIMKIN
Address Line 1:	FOLEY & LARDNER LLP
Address Line 2:	3000 K STREET, NW, SUITE 600
Address Line 4:	WASHINGTON, D.C. 20007
ATTORNEY DOCKET NUMBER:	120188-0185
NAME OF SUBMITTER:	MICHELE M. SIMKIN
SIGNATURE:	/Michele M. Simkin/
DATE SIGNED:	04/02/2020
Total Attachments: 4	
source=120188_0185_ASSIGNMENT_QUANTICEL_TO_CELGENE#page4.tif	
source=120188_0185_ASSIGNMENT_QUANTICEL_TO_CELGENE#page5.tif	

source=120188_0185_ASSIGNMENT_QUANTICEL_TO_CELGENE#page6.tif

source=120188_0185_ASSIGNMENT_QUANTICEL_TO_CELGENE#page7.tif

ASSIGNMENT

WHEREAS I/WE,

QUANTICEL PHARMACEUTICALS, INC.

9393 Towne Centre Drive
San Diego, CA 92121
United States of America

respectively ("Assignor"), have made a certain new and useful invention as set forth in the U.S. and International Patent Application Numbers in the attached Exhibit A:

AND WHEREAS,

CELGENE QUANTICEL RESEARCH, INC.

9393 Towne Centre Drive
San Diego, CA 92121
United States of America

respectively ("Assignee"), is desirous of acquiring the entire right, title and interest in and to said invention and application, and in and to any and all Letters Patent of any country which may be obtained therefore;

NOW, THEREFORE, for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, transfer and set over unto Assignee, its legal representatives, successors, and assigns, the entire right, title and interest in and to said invention and application, including the right to claim priority under 35 U.S.C. §119 and/or §120 the right to sue for past infringement, as set forth in the above-mentioned application, including any continuations, continuations-in-part, divisions, reissues, re-examinations or extensions thereof, and in and to any and all patents of any country which may be issued for said invention;

UPON SAID CONSIDERATION, Assignor hereby agrees with the said Assignee that Assignor will not execute any writing or do any act whatsoever conflicting with these presents, and that Assignor will, at any time upon request, without further or additional consideration but at the expense of said Assignee, execute such additional assignments and other writings and do such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and render all necessary assistance in making application for and obtaining original, divisional, continuations, continuations-in-part, reexamined, reissued, or extended Letters Patent of any country on said invention, and in enforcing any rights or chooses in action accruing as a result of such applications or patents, by giving testimony in any proceedings or transactions involving such applications or patents, and by executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of the assigns and legal representatives of Assignor and Assignee;

PATENT

REEL: 052296 FRAME: 0084

The undersigned hereby grant(s) the firm of WILEY REIN LLP the power to insert on this Assignment any further identification, including the application number and filing date, which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

This Assignment may be executed in counterparts and all such counterparts shall constitute one and the same instrument.

AND Assignor requests the Commissioner of Patents and Trademarks to issue any Letters Patent of the United States which may be issued for said invention to said Assignee, its legal representatives, successors or assigns, as the sole owner of the entire right, title and interest in and to said patent and the invention covered thereby.

In witness thereof, this Assignment has been executed by the undersigned on the date(s) opposite the undersigned name(s).

QUANTICEL PHARMACEUTICALS, INC.
CELGENE QUANTICEL RESEARCH, INC.

Date Apr 8, 2016

Representative Name: Jeffrey A. Stafford, Ph.D.
Chief Scientific Officer

This assignment should preferably be acknowledged before a United States Consul or Notary Public. If not, then the execution by the representative should be witnessed by at least two other persons who should sign here.

Witness _____

Signature _____

Witness _____

Signature _____

Witness _____

Signature _____

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

CIVIL CODE § 1189


A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California)
 County of San Diego)
 On April 8, 2016 before me, Heidi R. Hamann, Notary Public,
 Date Here Insert Name and Title of the Officer
 personally appeared Jeffrey A. Stafford
 Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.



Signature Heidi R. Hamann
 Signature of Notary Public

Place Notary Seal Above

OPTIONAL

Though this section is optional, completing this information can deter alteration of the document or fraudulent reattachment of this form to an unintended document.

Description of Attached Document

Title or Type of Document: Assignment (Atty. Dkt. 87386 0001)
 Document Date: April 8, 2016 Number of Pages: _____
 Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer(s)

Signer's Name: <u>Jeffrey A. Stafford</u>	Signer's Name: _____
Corporate Officer — Title(s): _____	Corporate Officer — Title(s): _____
Partner — Limited General	Partner — Limited General
Individual Attorney in Fact	Individual Attorney in Fact
Trustee Guardian or Conservator	Trustee Guardian or Conservator
Other: _____	Other: _____
Signer Is Representing: _____	Signer Is Representing: _____

EXHIBIT A

ASSIGNMENT LISTING OF ACTIVE U.S. AND PCT APPLICATIONS

87386.0004\US	HISTONE DEMETHYLASE INHIBITORS	14/098,415	12/15/2013
87386.0004\US1	HISTONE DEMETHYLASE INHIBITORS	14/630,091	02/24/2015
87386.0004\US2	HISTONE DEMETHYLASE INHIBITORS	14/755,791	06/30/2015
87386.0004\US3	HISTONE DEMETHYLASE INHIBITORS	14/650,241	07/31/2015
87386.0005\US	HISTONE DEMETHYLASE INHIBITORS	14/134,989	12/19/2013
87386.0005\US1	HISTONE DEMETHYLASE INHIBITORS	14/653,818	08/28/2015
87386.0006\US	HISTONE DEMETHYLASE INHIBITORS	14/139,197	12/23/2013
87386.0006\US1	HISTONE DEMETHYLASE INHIBITORS	14/592,830	01/08/2015
87386.0006\US2	HISTONE DEMETHYLASE INHIBITORS	14/740,143	06/15/2015
87386.0006\US3	HISTONE DEMETHYLASE INHIBITORS	14/653,821	08/26/2015
87386.0007\US	HISTONE DEMETHYLASE INHIBITORS	14/774,329	09/10/2015
87386.0008\US	HISTONE DEMETHYLASE INHIBITORS	14/210,006	03/13/2014
87386.0008\US1	HISTONE DEMETHYLASE INHIBITORS	14/774,338	09/10/2015
87386.0008\US2	HISTONE DEMETHYLASE INHIBITORS	14/852,079	09/11/2015
87386.0009\US	HISTONE DEMETHYLASE INHIBITORS	14/774,335	03/12/2014
87386.0010\US	BROMODOMAIN INHIBITORS	14/517,705	10/17/2014
87386.0010\US1	BROMODOMAIN INHIBITORS	14/658,048	03/13/2015
87386.0010\US2	BROMODOMAIN INHIBITORS	14/789,881	07/01/2015
87386.0012\US	INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1	14/701,304	04/30/2015
87386.0012\US1	INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1	15/018,814	02/08/2016
87386.0013\US	HISTONE DEMETHYLASE INHIBITORS	14/751,007	06/25/2015
87386.0013\US1	HISTONE DEMETHYLASE INHIBITORS	14/963,754	12/09/2015
87386.0017\US	INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1	14/845,120	09/03/2015
87386.0018\US	HISTONE DEMETHYLASE INHIBITORS	14/855,269	09/15/2015
87386.0018\US1	HISTONE DEMETHYLASE INHIBITORS	15/070,938	03/15/2016
87386.0019\US	HISTONE DEMETHYLASE INHIBITORS	14/852,860	09/14/2015
87386.0020\US	HISTONE DEMETHYLASE INHIBITORS	14/855,950	09/16/2015
87386.0020\US1	HISTONE DEMETHYLASE INHIBITORS	15/071,050	03/15/2016
87386.0021\PRO	BROMODOMAIN INHIBITORS	62/148,098	04/15/2015
87386.0022\PRO	BROMODOMAIN INHIBITORS	62/151,205	04/22/2015
87386.0023\PRO	COMPOSITION COMPRISING AND INHIBITOR OF LYSINE SPECIFIC DEMETHYLASE-1	62/251,507	11/05/2015
87386.0024\PRO	HISTONE DEMETHYLASE INHIBITORS	62/271,654	12/28/2015
87386.0010\PCT	BROMODOMAIN INHIBITORS	PCT/US2014/061261	10/17/2014
87386.0011\PCT	INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1	PCT/US2014/069562	12/10/2014
87386.0012\PCT	INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1	PCT/US2015/028635	04/30/2015
87386.0013\PCT	HISTONE DEMETHYLASE INHIBITORS	PCT/US2015/037812	06/25/2015
87386.0014\PCT	INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1	PCT/US2015/038089	06/26/2015
87386.0015\PCT	INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1	PCT/US2015/038661	06/30/2015
87386.0016\PCT	INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1	PCT/US2015/038345	06/29/2015
87386.0017\PCT	INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1	PCT/US2015/048429	09/03/2015
87386.0018\PCT	HISTONE DEMETHYLASE INHIBITORS	PCT/US2015/050289	09/15/2015
87386.0020\PCT	HISTONE DEMETHYLASE INHIBITORS	PCT/US2015/050432	09/16/2015
87386.0020\PCT	HISTONE DEMETHYLASE INHIBITORS	PCT/US2015/049926	09/14/2015

13974701.2

PATENT

RECORDED: 04/02/2020

REEL: 052296 FRAME: 0097